Table 1

Clinical and laboratory findings for 42 patients with ankylosing spondylitis treated with infliximab

Finding

BASDAI

BASMI

BASFI

PatGA

PhysGA

NRS-P

ESR (mm/h)

CRP (mg/l)


At time point 1a


Mean ± SD

2.5 ± 1.8**

2.7 ± 2.0*

2.9 ± 2.4**

2.6 ± 1.5**

2.6 ± 2.1**

2.6 ± 2.1**

10.5 ± 7.3**

3.1 ± 4.2**

Median

2.4

2.0

2.5

4.0

2.0

2.0

8.0

1.1

Range

0.0 - 6.8

0.0 - 7.0

0.0 - 8.3

0.0 - 8.0

0.0 - 4.0

0.0 - 7.0

2.0 - 32.0

0.0 - 19.0


At time point 2a


Mean ± SD

6.1 ± 1.4**

3.2 ± 2.2*

5.8 ± 1.8**

6.9 ± 2.1**

7.0 ± 1.5**

7.1 ± 1.7**

31.5 ± 29.7**

20.7 ± 23.7**

Median

6.2

3.0

5.7

7.0

7.0

7.0

23.0

14.0

Range

4.0 - 9.2

0.0 - 9.0

1.2 - 9.1

4.0 - 10.0

4.0 - 10.0

0.0 - 10.0

4.0 - 150.0

0.3 - 126.0


Change between time points 1 and 2


Mean ± SD

3.6 ± 1.7

0.5 ± 1.5

2.9 ± 2.0

4.3 ± 1.9

4.4 ± 1.8

4.5 ± 2.2

21.0 ± 29.7

17.6 ± 23.4

Median

3.6

0.5

2.5

4.0

4.0

4.0

12.0

11.5

Range

-1.2 - 6.7

-4.0 - 3.0

-0.5 - 7.8

-2.0 - 8.0

-2.0 - 8.0

-1.0 - 8.0

-6.0 - 146.0

-6.3 - 123.0


aTime point 1 is the time point at which infliximab treatment was discontinued; time point 2 is that when retreatment began. *P < 0.05, **P < 0.001, when means at time points 1 and 2 are compared. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Function Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; NRS-P, numerical rating scale for pain; PatGA, patient's global assessment; PhysGA, physician's global assessment; SD, standard deviation.

Baraliakos et al. Arthritis Research & Therapy 2005 7:R439-R444   doi:10.1186/ar1693

Open Data